Compare Edwards Lifesciences Corporation Common Stock (EW) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $61.21 (market cap $44.68B). The key difference: Edwards Lifesciences Corporation Common Stock and JPMorgan Nasdaq Equity Premium Income ETF are close in size by market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| EW | JEPQ | |
|---|---|---|
Market Cap | $49.44B | $44.68B |
Volume | 3,508,027 | 6,315,250 |
Sector | Health | Income / Options Overlay |
52-Week High | $95.18 | $61.46 |
52-Week Low | $72.65 | $53.77 |
Enterprise Value | $45.90B | — |
Typical Hold Time | — | 65 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JEPQ trades at $61.27 with minimal daily movement (+0.03%), showing technical bullish momentum with strong moving average support. The ETF maintains an estimated 11% annualized yield through its covered call strategy on Nasdaq-100 stocks, though recent oscillators suggest potential near-term consolidation. Recent news highlights JEPQ's popularity among income-focused investors seeking monthly distributions from tech exposure.
JEPQ offers high income generation but faces trade-offs between yield and capital appreciation. The fund's performance depends heavily on market volatility for option premium income, with limited upside during strong bull markets. Key risks include concentrated tech exposure and variable dividend payments that fluctuate with market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
